Eli Lilly and Company $LLY Shares Purchased by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. boosted its position in Eli Lilly and Company (NYSE:LLY) by 8.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,284 shares of the company’s stock after purchasing an additional 703 shares during the period. Geneos Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $7,668,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. PNC Financial Services Group Inc. lifted its position in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. GAMMA Investing LLC boosted its holdings in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock worth $12,278,292,000 after buying an additional 14,852,076 shares in the last quarter. Nuveen LLC bought a new stake in Eli Lilly and Company during the first quarter worth approximately $4,613,912,000. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Eli Lilly and Company by 15.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company’s stock worth $5,469,527,000 after buying an additional 969,376 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Guggenheim reduced their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Morgan Stanley restated an “overweight” rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Cantor Fitzgerald reduced their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $950.17.

Eli Lilly and Company Stock Up 1.5%

Shares of NYSE:LLY opened at $749.99 on Wednesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $942.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $709.84 billion, a PE ratio of 49.02, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47. The firm has a 50 day simple moving average of $742.49 and a 200 day simple moving average of $779.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 EPS. The company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.